Opinion|Videos|June 9, 2025
The importance of studying efficacy and safety of treatment in Black patients with mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Research highlights the need for personalized treatment in mHSPC, addressing variations in drug efficacy across diverse populations for optimal patient care.
Advertisement
Episodes in this series
Importance of Personalized Medicine
Key Themes:
- Drug efficacy and safety may vary across different subpopulations.
- Considerations extend beyond race to other demographic factors.
- There is a potential need for personalized dosing approaches.
- Targeted studies are crucial for clinician confidence and patient reassurance.
Key Points for Physicians:
- Consider individual characteristics beyond race when selecting treatments.
- Recognize the growing importance of personalized medicine approaches.
- Communicate clearly with patients about evidence supporting treatment recommendations.
Notable Insights: The discussion of personalized medicine extends beyond race to consider the broader landscape of individual variation in drug response and tolerability.
Clinical Significance: Advancing personalized medicine approaches, including subgroup-specific analyses, will improve cancer care by appropriately tailoring treatments to individual and population characteristics.
Advertisement
Related to this article
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5